In a buyout that marks the latest endorsement for targeted cancer drugs—and, potentially, the increasing utility of broad cancer DNA tests—Roche this morning agreed to acquire San Diego biotech Ignyta in an all-cash deal valued at $1.7 billion.
{iframe}https://www.xconomy.com/san-diego/2017/12/22/roche-bets-1-7b-more-on-precision-oncology-with-ignyta-deal/?utm_source=Xconomy&utm_campaign=579d534cd0-NEWSLETTER_all_stories&utm_medium=email&utm_term=0_2aa91c0bc9-579d534cd0-288460969&mc_cid=579d534cd0&mc_eid=7fe06a878f{/iframe}